Raymond James initiated coverage of Oncolytics with an Outperform rating and $3 price target. Oncolytics is looking to effect extraordinary change in pancreatic cancer, an area of extraordinary unmet need, the analyst tells investors in a research note. Clinically meaningful outcomes of new therapies in this area would represent a gigantic leap forward for patients, the firm adds, noting that in early clinical setting, Oncolytics has yielded compelling signals of therapeutic efficacy for their proprietary medicine, motivating the high-risk, high-reward pursuit of later-stage development.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics Biotech Showcases at Oncology Event
- Oncolytics Biotech Showcases at Oncology Conference
- Oncolytics Biotech Shows Promising Cancer Drug Progress
- Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- Oncolytics Biotech Expands Pancreatic Cancer Study